Maftivimab is a Zaire ebolavirus glycoprotein-directed human monoclonal antibody that is part of the fixed-dose combination atoltivimab/maftivimab/odesivimab that is used for the treatment of Zaire ebolavirus (Ebola virus).
References
External links "Maftivimab". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 29 August 2021. "Statement on a nonproprietary name adopted by the USAN Council USAN (FG-103) Maftivimab" (PDF).
